Shopping Cart
Remove All
Your shopping cart is currently empty
CCT251455, the mitotic kinase monopolar spindle 1 (MPS1/TTK) inhibitor, is a potent (IC50=3 nM) and specific chemical tool.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,820 | 8-10 weeks | 8-10 weeks | |
| 50 mg | $2,380 | 8-10 weeks | 8-10 weeks | |
| 100 mg | $3,100 | 8-10 weeks | 8-10 weeks |
| Description | CCT251455, the mitotic kinase monopolar spindle 1 (MPS1/TTK) inhibitor, is a potent (IC50=3 nM) and specific chemical tool. |
| Targets&IC50 | MPS1:3 nM |
| In vitro | CCT251455 is a potent MPS1 inhibitor that exhibits high selectivity across a broad kinase profiling panel and excellent translation of in vitro biochemical potency to cellular potency compared to the isolated MPS1 enzyme (P-MPS1 IC50 of 0.04 μM and HCT116 GI50 of 0.16 μM).[1] |
| In vivo | Methods: Mice bearing HCT116 human colon cancer xenografts were treated with CCT251455 (50, 75, and 100 mg/kg, orally, twice daily). Results: CCT251455 was well tolerated at all doses and inhibited MPS1 activity in mice; the observed reduction in phospho-histone H3 inhibition was consistent with the reduction in total plasma and tumor tissue exposure measured in the same experiment. [1] |
| Synonyms | CCT 251455 |
| Molecular Weight | 503.98 |
| Formula | C26H26ClN7O2 |
| Cas No. | 1400284-80-1 |
| Smiles | O=C(OC(C)(C)C)N1C=2C=C(N=CC2C=C1C=3C=NN(C3)C)NC=4C=CC(=CC4Cl)C5=CN=CN5C |
| Relative Density. | 1.34 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (198.42 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (6.55 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.